Edaravone derivatives containing NO-donor functions.

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Cardiovascular Research

Background:

• Cardiovascular disorders often involve endothelial dysfunction, characterized by reduced nitric oxide (NO) bioavailability (EDRF deficiency).
• Increased reactive oxygen species (ROS) contribute to oxidative stress, exacerbating cardiovascular pathologies.
• Edaravone is a known antioxidant, but its application in cardiovascular diseases requires further development.

Purpose of the Study:

• To synthesize and characterize novel polyvalent drugs by conjugating edaravone with nitric oxide-donor moieties.
• To evaluate the antioxidant and vasodilatory properties of these novel compounds.
• To investigate the structure-activity relationships, particularly the role of lipophilicity, in modulating their biological effects.

Main Methods:

• Synthesis of novel edaravone-NO donor conjugates.
• In vitro assessment of antioxidant capacity using relevant assays.
• Evaluation of vasodilation effects in isolated vascular preparations, assessing NO-dependency.
• Computational analysis of molecular descriptors, including lipophilicity, and correlation with activity.

Main Results:

• The synthesized compounds exhibited significant antioxidant power, directly linked to the edaravone substructure.
• All compounds demonstrated nitric oxide-dependent vasodilator properties.
• Molecular descriptor analysis indicated that lipophilicity is a key factor modulating the antioxidant activity of these novel drugs.

Conclusions:

• The novel polyvalent drugs possess dual antioxidant and vasodilatory actions, attributed to the edaravone and NO-donor components, respectively.
• These compounds show promise for treating cardiovascular conditions associated with EDRF deficiency and ROS excess.
• Lipophilicity represents a critical parameter for optimizing the therapeutic potential of these agents in cardiovascular medicine.